This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

QPI-1002

Quark Pharmaceuticals, Inc.

Drug Names(s): DGFi, AKIi-5, I5NP

Description: QPI-1002 (formerly AKIi-5 or I5NP) is an siRNA that temporarily and reversibly inhibits the activity of the p53 gene, which is associated with DNA repair and apoptosis.

p53 is a transcription factor that is activated by stresses such as DNA damage and hypoxia, leading to the activation of cellular pathways that induce either cell cycle arrest, cell senescence, or apoptosis in damaged cells. In acute settings, the temporary inhibition of p53 at the time of injury delays the induction of cell death, thereby allowing natural repair mechanisms to restore normal DNA and cellular integrity.

Preclinical studies have shown that p53-targeted siRNA can be effective in protecting kidneys from injury due to cold ischemia or lack of oxygen during organ preservation and storage between removal from the donor and implantation.

Deal Structure: Quark and Silence
In April 2005, Quark and Silence Therapeutics signed an Option and Licence Agreement, which provided Quark with access to Silence Therapeutics' novel proprietary siRNA technology, AtuRNAi.

In December 2010, Silence announced that it has reached agreement with Quark whereby Silence is due to receive milestone payments of up to $1.5 million in relation to the option agreement signed between Quark and Novartis for QPI-1002. Silence anticipates that its share of future milestone payments relating to Quark's license agreement with Novartis could reach $80 million.

Quark and Alnylam
In September 2006, Alnylam Pharmaceuticals announced that it granted Quark Biotech InterfeRx licenses to discover, develop, and commercialize RNAi therapeutics targeting the p53 and RTP801 genes for certain diseases. Detailed financial terms were not disclosed, but include upfront, annual, and milestone payments, as well as royalties on sales of any products covered...See full deal structure in Biomedtracker

Partners: Silence Therapeutics plc Alnylam Pharmaceuticals, Inc.


QPI-1002 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug